BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37351976)

  • 21. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
    Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
    Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
    Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
    World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.
    Ouzaid I; Capitanio U; Staehler M; Wood CG; Leibovich BC; Ljungberg B; Van Poppel H; Bensalah K;
    Eur Urol Oncol; 2019 Mar; 2(2):141-149. PubMed ID: 31017089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 27. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma.
    Kim SH; Park WS; Park B; Pak S; Chung J
    Front Oncol; 2019; 9():413. PubMed ID: 31179242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Efficacy of Surgical Metastasectomy for Solitary Metastasis of Renal Cell Carcinoma.
    Suzuki K; Hara T; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Urol Int; 2022; 106(4):397-403. PubMed ID: 34134119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment.
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Int; 2007; 79(2):145-51. PubMed ID: 17851285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
    Fluhrer H; Hutterer GC; Golbeck S; Stidl M; Niedrist T; Pichler R; Mischinger J; Seles M; Mannweiler S; Spiegelberg J; Bauernhofer T; Jost PJ; Ahyai S; Zigeuner R; Pichler M; Barth DA
    Ther Adv Med Oncol; 2022; 14():17588359221134065. PubMed ID: 36425872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era.
    Lyon TD; Thompson RH; Shah PH; Lohse CM; Boorjian SA; Costello BA; Cheville JC; Leibovich BC
    J Urol; 2020 Feb; 203(2):275-282. PubMed ID: 31393812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis.
    Palumbo C; Pecoraro A; Knipper S; Rosiello G; Tian Z; Shariat SF; Simeone C; Briganti A; Saad F; Berruti A; Antonelli A; Karakiewicz PI
    Anticancer Res; 2019 Aug; 39(8):4357-4361. PubMed ID: 31366530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes and prognostic factors following the surgical resection of renal cell carcinoma spinal metastases.
    Kato S; Demura S; Murakami H; Yoshioka K; Shinmura K; Yokogawa N; Shimizu T; Kawahara N; Tsuchiya H
    Cancer Sci; 2021 Jun; 112(6):2416-2425. PubMed ID: 33780597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy.
    Mizuno R; Takamatsu K; Yasumizu Y; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Asanuma H; Mikami S; Oya M
    Urol Int; 2022; 106(11):1145-1149. PubMed ID: 35139522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The significance of metastasectomy in patients with metastatic renal cell carcinoma].
    Miyata H; Shinohara N; Murahashi N; Tsuchiya K; Miyajima N; Maruyama S; Abe T; Kaga K; Hirano S; Nonomura K
    Hinyokika Kiyo; 2015 Feb; 61(2):49-54. PubMed ID: 25812593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
    Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
    Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
    Maisel F; Smolle MA; Mollnar S; Riedl JM; Barth DA; Seles M; Terbuch A; Rossmann CH; Eisner F; Mannweiler S; Hutterer G; Zigeuner R; Pummer K; Smolle-Jüttner FM; Lindenmann J; Stotz M; Gerger A; Jost PJ; Bauernhofer T; Pichler M; Posch F
    Clin Genitourin Cancer; 2022 Aug; 20(4):344-353. PubMed ID: 35443915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma.
    Lyon TD; Roussel E; Sharma V; Carames G; Lohse CM; Costello BA; Boorjian SA; Thompson RH; Joniau S; Albersen M; Leibovich BC
    Eur Urol Oncol; 2023 Feb; 6(1):76-83. PubMed ID: 36509653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.